Clinical Scorecard: Analysis of Real-World Data Challenges Assumptions About IRD Penetrance
At a Glance
| Category | Detail |
|---|---|
| Condition | Inherited Retinal Degenerations (IRDs) |
| Key Mechanisms | Incomplete penetrance of Mendelian IRD-associated genetic variants influenced by additional genetic or environmental factors |
| Target Population | Individuals carrying IRD-associated genotypes in the general population |
| Care Setting | Genetic testing and ophthalmology clinical settings with access to genomic and retinal imaging data |
Key Highlights
- Only 9% to 28% of individuals with IRD-associated genotypes show clinical evidence of retinal disease depending on diagnostic criteria.
- IRD-compatible genotypes may be present in 0.7% to 2.1% of the general population, substantially higher than clinically diagnosed IRD prevalence.
- Genetic variants in PRPH2, RPGR, and RHO show significant enrichment for retinal disease, while BEST1 and RP1 do not.
Guideline-Based Recommendations
Diagnosis
- Use nested ICD-9 and ICD-10 code sets (IRD-specific, retinopathy, screening) to assess disease annotation frequency in genetically at-risk individuals.
- Incorporate retinal imaging (color fundus photography, OCT) to corroborate clinical penetrance estimates.
Management
- Recognize incomplete penetrance and variable expressivity when interpreting genetic test results for IRDs.
- Avoid presymptomatic screening based solely on genetic findings due to low positive predictive value.
Monitoring & Follow-up
- Consider longitudinal clinical and imaging follow-up for individuals with IRD-associated variants to detect late-onset or subtle retinal changes.
Risks
- Potential overestimation of disease risk from genetic testing alone due to incomplete penetrance.
- Limitations in imaging (posterior pole focus) may miss peripheral retinal manifestations.
Patient & Prescribing Data
Individuals identified with pathogenic or likely pathogenic IRD-associated variants from large genomic biobanks
Low penetrance suggests that genetic findings alone have limited predictive value for disease manifestation, highlighting the need for personalized risk assessment and cautious interpretation of genetic testing results.
Clinical Best Practices
- Interpret IRD genetic test results within the context of clinical findings and family history due to incomplete penetrance.
- Use comprehensive phenotyping including retinal imaging to improve disease detection in variant carriers.
- Be cautious about presymptomatic genetic screening given low positive predictive value.
- Consider research participation to identify genetic or environmental modifiers influencing IRD expression.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
